Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Osteopore Ltd. ( (AU:OSX) ) has shared an announcement.
Osteopore reported first-quarter 2026 revenue of AUD 754,000, representing growth of 10% quarter-on-quarter and 4% year-on-year, underscoring steady expansion of its commercial footprint. The company also established 3D printing services as an additional revenue stream, extending its activities along the value chain and positioning itself for more diversified income.
New distribution partnerships were signed with Essex-Bio’s Majeton in China, Medprin in Latin America, and MontsMed in Hong Kong, enhancing Osteopore’s access to key international markets. This growing global partner network supports broader adoption of its regenerative implant technologies and is expected to strengthen the company’s competitive position and long-term growth prospects.
More about Osteopore Ltd.
Osteopore Ltd. is an ASX-listed medical technology company that manufactures regenerative implants designed to enable natural tissue regeneration. The company focuses on leveraging 3D printing and biomaterials to serve healthcare markets requiring advanced cranial, orthopedic, and other reconstructive solutions.
Average Trading Volume: 21,186,719
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.38M
For an in-depth examination of OSX stock, go to TipRanks’ Overview page.